InvestorsHub Logo
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
harry crumb Free
05/02/23 9:59 AM
profile icon
harry crumb Free
04/26/23 7:29 AM
profile icon
harry crumb Free
04/25/23 1:33 PM
profile icon
harry crumb Free
04/25/23 1:31 PM
profile icon
harry crumb Free
04/24/23 3:03 PM
profile icon
harry crumb Free
04/24/23 12:05 PM
profile icon
harry crumb Free
04/24/23 10:00 AM
profile icon
harry crumb Free
04/06/23 9:43 AM
profile icon
harry crumb Free
04/05/23 10:30 AM
profile icon
harry crumb Free
03/30/23 1:34 PM
profile icon
winna Free
03/30/23 1:05 PM
profile icon
harry crumb Free
03/30/23 12:19 PM
profile icon
harry crumb Free
03/29/23 7:54 AM
profile icon
harry crumb Free
03/28/23 9:16 PM
profile icon
winna Free
03/28/23 3:36 PM
profile icon
harry crumb Free
03/28/23 1:39 PM
profile icon
harry crumb Free
03/28/23 11:21 AM
profile icon
harry crumb Free
03/27/23 8:03 PM
profile icon
vieuxcarre Free
03/27/23 3:08 PM
profile icon
harry crumb Free
03/27/23 12:06 PM
profile icon
harry crumb Free
03/23/23 2:51 PM
profile icon
harry crumb Free
03/23/23 1:12 PM
profile icon
harry crumb Free
03/22/23 11:47 AM
profile icon
harry crumb Free
03/22/23 11:45 AM
profile icon
harry crumb Free
03/22/23 10:54 AM
profile icon
harry crumb Free
03/21/23 1:41 PM
profile icon
winna Free
03/21/23 12:29 PM
profile icon
harry crumb Free
03/21/23 11:06 AM
profile icon
harry crumb Free
03/20/23 2:40 PM
profile icon
vieuxcarre Free
03/17/23 5:12 PM
profile icon
harry crumb Free
03/17/23 4:54 PM
profile icon
harry crumb Free
03/17/23 4:44 PM
profile icon
harry crumb Free
03/17/23 4:43 PM
profile icon
winna Free
03/17/23 4:02 PM
profile icon
sgunderbarth PremiumMember
03/15/23 11:08 AM
profile icon
harry crumb Free
03/10/23 1:30 PM
profile icon
harry crumb Free
03/09/23 4:13 PM
profile icon
harry crumb Free
03/09/23 4:13 PM
profile icon
harry crumb Free
03/09/23 4:07 PM
profile icon
harry crumb Free
03/09/23 4:06 PM
profile icon
harry crumb Free
03/09/23 3:22 PM
profile icon
harry crumb Free
03/01/23 9:09 AM

Ocugen Inc (OCGN) RSS Feed

Followers
226
Posters
607
Posts (Today)
0
Posts (Total)
5748
Created
11/13/15
Type
Free
Moderators sgunderbarth

"A fully integrated, patient-centric biotech company focused on vaccines in support of public health and gene and cell therapies targeting unmet medical needs through Courageous Innovation."
 


IMPORTANT NEWS:
__________

OCUGEN MUCOSAL VACCINE CANDIDATE OCU500 SELECTED BY NIH/NIAID PROJECT NEXTGEN FOR INCLUSION IN CLINICAL TRIALS

What is OCU500?
"
The OCU500 vaccine series is based on a novel ChAd platform designed to reduce transmission and protect against new variants with long-term durability."

Inhalation technology as a differentiator
"Multiple preclinical studies using Ocugen’s vector demonstrated vaccine-induced high neutralizing and effector responses. Clinical studies using a similar vector administered via the inhalation platform showed mucosal antibodies, systemic antibodies, and durable immune response up to 1 year with 1/5 of the dose compared to the same vaccine given via intramuscular administration. The inhaled method offers the potential for broad, durable protection from severe disease and reduction in transmission."

__________

 

Who is Connie?  "Ms. Collingsworth has been a primary advisor to Bill GatesMelinda French Gates, and Warren Buffett regarding governance. During her tenure with the Bill and Melinda Gates Foundation, she designed and implemented the core operational infrastructure and created the intellectual property strategy known as “Global Access,” as well as advising on the creation of a $2.5 billion strategic investment fund."
 

 


DD LINKS:
SEC Filings
ClinicalTrials.org

LinkedIn

Phase 3 safety study for our ChAd vector vaccine via Nasal delivery: 
https://www.nature.com/articles/s41541-023-00717-8 

Phase 3 trial for our Inhalation delivery device: 

https://www.prnewswire.com/news-releases/convidecia-phase-iii-results-published-in-the-lancet-301450673.html 

Phase1 efficacy results using both our ChAd vector vaccine and our inhalation delivery device. 
Quote- "so efficient at targeting the lungs and upper airways that it can achieve maximum protection with a small fraction of the dose of current vaccines - possibly as little as 1 per cent - meaning a single batch of vaccine could go 100 times farther, the researchers say.” 

https://brighterworld.mcmaster.ca/articles/researchers-confirm-newly-developed-inhaled-vaccine-delivers-broad-protection-against-sars-cov-2-variants-of-concern/


 


PARTNERS:



 

PATENTS:


 


(ibox under construction. Updated Nov 4, 2023)

*The above ibox section is managed by sgunderbarth. Not financial advice. For information purposes only. I am not a licensed financial advisor or broker, and have no affiliation with Ocugen. Never invest more than you're willing to lose. Not selling. 
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
New Post